Specialized Investment Focus Nextech Invest's exclusive focus on oncology therapeutics presents a prime opportunity for companies providing technology, research tools, or services tailored to cancer drug development and clinical trials, aligning with their core investment interests.

Growing Portfolio With recent investments totaling hundreds of millions into innovative biotech firms like Fogpharma, Delphia, and ITM, Nextech is actively expanding its portfolio, signaling ongoing funding opportunities for partners supporting biotech research, early-stage pharma, and related innovations.

Geographic Expansion Although headquartered in Zurich, Nextech’s investments are predominantly US and European-based, creating a receptive market for regional biotech solutions, CROs, and tech providers targeting these key markets to support portfolio company growth.

Alliance with Top Investors Nextech’s collaboration with leading venture firms and institutional investors like GV, Polaris, Temasek, and BlackRock indicates a strong network and potential for co-investment, partnership, or service opportunities within the biotech funding ecosystem.

Market Trend Alignment Their focus on precision oncology and radiopharmaceuticals aligns with current market trends emphasizing targeted cancer therapies and personalized medicine, suggesting sales opportunities for innovative research tools, diagnostics, and precision medicine platforms.